(Total Views: 322)
Posted On: 04/05/2017 6:06:56 AM
Post# of 72448
I wonder how many have done a side by side of the Kevetrin poster that was presented at ASCO in 2013 to the one presented yesterday at the AACR conference. I have a copy of ASCO's, haven't looked to see if it's still on the Cellceutix website.
I'll just say, yesterdays poster was awesome. VERY well put together.
I was just curious. There really is no comparison since in 2013 it was "A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile,
a novel p53 targeted therapy, in patients with advanced solid tumors"
and yesterday... "Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies"
I'll just say, yesterdays poster was awesome. VERY well put together.
I was just curious. There really is no comparison since in 2013 it was "A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile,
a novel p53 targeted therapy, in patients with advanced solid tumors"
and yesterday... "Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies"
Quote:
https://static1.squarespace.com/static/571535...7MAR30.pdf
Poster from the presentation.
(2)
(0)
